There isn’t a single “best” hormone therapy for menopause. The right choice depends on your symptoms, your age, how long ago your periods stopped, whether you still have a uterus, and your personal health history. That said, the evidence does point to some clear winners in terms of safety profile: transdermal estradiol (a patch, gel, or spray) paired with micronized progesterone consistently comes out ahead of older oral and synthetic options across multiple measures of risk.
Why Timing Matters More Than the Drug
The most important factor in whether hormone therapy helps or harms you isn’t which product you choose. It’s when you start. The “timing hypothesis,” now supported by reanalysis of data from the Women’s Health Initiative and reinforced in the 2022 position statement from the North American Menopause Society, is straightforward: if you’re under 60 or within 10 years of your last period, the benefits of hormone therapy generally outweigh the risks for treating hot flashes and preventing bone loss.
Start it later and the equation flips. Women who began estrogen plus a progestin within 10 years of menopause showed a trend toward reduced coronary heart disease (a hazard ratio of 0.76), while women on estrogen alone in that same window saw an even more favorable signal (hazard ratio 0.59). Women who started more than 20 years after menopause, or at age 70 and older, experienced increased coronary risk instead. This window of opportunity is central to every prescribing decision today.
Patches and Gels vs. Pills
Estrogen can be delivered through the skin (patches, gels, sprays) or swallowed as a pill. Both relieve hot flashes effectively, but their safety profiles differ in one critical area: blood clots. A meta-analysis of 15 observational studies found that oral estrogen was associated with a 63% higher risk of venous thromboembolism and roughly double the risk of deep vein thrombosis compared to transdermal estrogen. Oral estrogen also showed a possible increase in stroke risk, though the data on heart attacks showed no clear difference between the two.
The reason is biological. Oral estrogen passes through the liver first, where it stimulates clotting factors and inflammatory proteins. Transdermal estrogen enters the bloodstream directly, bypassing that liver effect. For women who are overweight, have a history of migraines with aura, or carry other clotting risk factors, the patch or gel is a particularly important distinction. Many clinicians now default to transdermal delivery for all patients simply because the clot risk is lower with no trade-off in symptom relief.
Micronized Progesterone vs. Synthetic Progestins
If you still have a uterus, you need a progestogen alongside estrogen to protect the uterine lining from overgrowth. Here, the type of progestogen matters significantly. The synthetic progestin used in the original Women’s Health Initiative trial (medroxyprogesterone acetate) was the component most responsible for the breast cancer risk that made headlines in 2002. Micronized progesterone, which is chemically identical to the progesterone your body produced before menopause, has a notably different track record.
A meta-analysis of cohort and case-control studies found that women using estrogen combined with micronized progesterone had a 33% lower breast cancer risk compared to women using estrogen combined with synthetic progestins (relative risk 0.67). In one population-based study, estrogen plus progesterone showed no significant increase in breast cancer at all, while estrogen plus a synthetic progestin trended toward a 57% increase. Beyond breast tissue, the differences extend to metabolism: in the PEPI trial, micronized progesterone did not erase estrogen’s beneficial effects on HDL cholesterol the way synthetic progestins did. Blood pressure, weight, and markers of inflammation and clotting also remained unchanged with micronized progesterone in a randomized, placebo-controlled trial.
The bottom line: if you need a progestogen, micronized progesterone (sold under brand names like Prometrium) has the strongest safety signal.
Vaginal Estrogen for Localized Symptoms
Not every menopause symptom requires systemic hormone therapy. Vaginal dryness, painful sex, urinary urgency, and recurrent urinary tract infections are caused by thinning tissue in the vagina and urinary tract as local estrogen levels drop. Low-dose vaginal estrogen, available as creams, tablets, rings, and softgel inserts, treats these symptoms directly with very little absorption into the bloodstream.
How little? The lowest available dose (a 4-microgram vaginal insert) produces blood estradiol levels of only 3.6 to 3.9 picograms per milliliter, barely above postmenopausal baseline. Even the 10-microgram dose stays in the range of 4.6 to 14.8 pg/mL depending on formulation, well below what oral or transdermal products produce. Because systemic absorption is so minimal, low-dose vaginal estrogen generally does not require supplemental progesterone and is considered safe even for many women with a history of breast cancer, though this is an area where individual risk assessment with your provider matters.
If vaginal and urinary symptoms are your primary complaint, vaginal estrogen alone may be all you need.
Bioidentical vs. Compounded Hormones
The term “bioidentical” simply means the hormone molecule is structurally identical to what your body makes. FDA-approved products like estradiol patches and micronized progesterone capsules are bioidentical. They’re manufactured in standardized doses, tested for safety and potency, and carry FDA-mandated labeling about risks.
Compounded bioidentical hormone therapy (CBHT) is a different story. These are custom-mixed formulations prepared by compounding pharmacies, often marketed as more “natural” or personalized. They use the same molecules, but they are not FDA-regulated, which means they don’t undergo the same quality testing, don’t carry standardized safety warnings, and have limited data on safety and efficacy. The appeal of compounding is understandable: women want individualized care. But the hormones themselves are available in FDA-approved versions, and the compounded route trades regulatory oversight for customization that isn’t always necessary. Salivary hormone testing, often used to guide compounded prescriptions, has not been validated as an accurate way to dose hormones.
Bone Protection
Hormone therapy is one of the most effective ways to protect bone density during and after the menopausal transition. It reduces the risk of vertebral fractures by about 40%, hip fractures by 30%, and all osteoporotic fractures combined by 20 to 30% compared to calcium and vitamin D alone. In the Women’s Health Initiative, hormone therapy prevented 5 hip fractures, 18 wrist fractures, and a total of 47 fragility fractures per 10,000 women per year.
Bone protection is a secondary benefit for women already taking hormone therapy for hot flashes, but it’s rarely recommended as a first-line treatment for osteoporosis alone because the risks of long-term use must be weighed. For women who start hormone therapy during the timing window and also happen to have low bone density, however, this is a meaningful bonus.
Who Should Not Use Systemic Hormone Therapy
Some conditions rule out systemic hormone therapy entirely. These include undiagnosed abnormal uterine bleeding, a high risk of venous thromboembolism, a history of heart attack, stroke, or unstable coronary disease, poorly controlled high blood pressure, active liver disease or liver failure, and a history of estrogen-sensitive cancers such as breast cancer. Pregnancy is also an absolute contraindication, and women with meningioma should not use progestogen therapy.
For women with these conditions who still struggle with hot flashes, non-hormonal options exist.
Non-Hormonal Alternatives
The newest non-hormonal option for hot flashes is fezolinetant (brand name Veozah), FDA-approved in 2023. It works by a completely different mechanism than estrogen: it blocks a receptor in the brain’s temperature-control center that becomes overactive after menopause, directly targeting the neural pathway responsible for hot flashes rather than replacing missing hormones.
In two clinical trials, women taking fezolinetant experienced a reduction of about 5 to 7.5 fewer moderate-to-severe hot flashes per day by week 12, a statistically significant and clinically meaningful improvement over placebo (which saw roughly 2.5 fewer hot flashes per day on its own). The severity of remaining hot flashes also dropped significantly. This makes fezolinetant a genuine option for women who can’t or prefer not to use hormones, though it does require liver function monitoring.
Older non-hormonal options include certain antidepressants (SSRIs and SNRIs), the nerve-pain medication gabapentin, and the blood-pressure drug clonidine. These can reduce hot flash frequency by 40 to 60%, which is meaningful but typically less effective than estrogen or fezolinetant.